• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

SCOLR Pharma, Inc., a pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold. The company is also developing IR Raloxifene for osteoporosis; ER Ondansetron, an anti-nausea drug; ER Phenylephrine a decongestant; and ER Niacin for cardiovascular disorders. In addition, it provides various formulation products for applications, including expectorant analgesic, sleep aid, cough-cold, decongestant and antihistamine, hypercholesterolemia and hypertriglyceridemia, pain management, beta-blockers, Ca Channel blockers, Alzheimer?s disease, schizophrenia/bi-polar, diabetes, motion sickness, asthma, and bronchodilator. SCOLR Pharma, Inc. has a strategic alliance with Perrigo Company of South Carolina, Inc. for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States; and research collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir for the treatment of seasonal and life threatening influenza. The company was formerly known as SCOLR, Inc. and changed its name to SCOLR Pharma, Inc. in July 2004. SCOLR Pharma, Inc. was founded in 1983 and is headquartered in Bothell, Washington.

YES
     
DDD (3D Systems Corp)
Last Trade 11.38 Date 1/24/2020
Change % -3.15 % Price Change -0.37
Open 11.77 52 Week High 14.5
High 11.98 52 Week Low 6.465
Low 11.2 Type stock
Volume 2779182 Average Volume 1731904
Prev Close 11.75 Stock Exchange NYSE
Bid 11.35 Ask 11.4
Bid Size 1 Ask Size 1
1st Yr Estimated EPS Growth 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 4.3468 Book Value Yield 0.382
Buy Back Yield CAPE Ratio
Cash Return -0.0104 Cash Flow per Share 0.157
Cash Flow Yield 0.0138 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.0536 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue EV / Pre Tax Income
EV / Revenue 2.0487 EV / Total Asset 1.6067
Expected Dividend Growth Rate Free Cash Flow per Share -0.1216
Free Caash Flow Ratio Free Cash Flow Yield -0.0107
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 2.618031 PB Ratio 10 Year Growth 0.009092
PB Ratio 3 Year Growth 2.405781 Cash Ratio 3 Year Average 1080.1228
Price to Cash Flow Ratio 72.484166 PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 92.139457 PE Ratio 10 Year Growth
PE Ratio 10 Year High 305.793884 PE Ratio 10 Year Low 18.367347
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg 223.265064 PE Ratio 5 Year High 295.454545
PE Ratio 5 Year Low 142.45 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 74.94644 Price Change 1 Month 1.300571
Price to Cash Ratio 10.560031 Price / EBITDA
Price to Sales Ratio 2.000842 Price to Sales Ratio 10 Year Growth -0.00988
Price to Sales Ratio 3 Year Avg 2.140678 Price to Sales Ratio 5 Year Avg 223.265064
Sale per Share 5.6876 Sales Yield 0.4998
Sustainable Growth Rate -0.1265 Tangible Book Value per Share 2.0757
Tangible Book Value per Share 3 year Avg 2.3268 Tangible Book Value per Share 5 year Avg 2.6034
Total Asset per Share 6.9478 Total Yield
Working Capital per Share 1.8621 Working Capital per Share 3 Year Avg 1.9164
Working Capital per Share 5 Year Avg 2.2849 Beta 2.615663